Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne C. Whitfield sold 2,137 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $107,085.07. Following the completion of the transaction, the insider now owns 46,355 shares in the company, valued at approximately $2,322,849.05. This represents a 4.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Tarsus Pharmaceuticals Price Performance
NASDAQ TARS opened at $49.91 on Friday. The business's fifty day moving average is $48.54 and its 200 day moving average is $45.06. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The company has a market capitalization of $1.92 billion, a PE ratio of -13.10 and a beta of 1.05.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.
Institutional Trading of Tarsus Pharmaceuticals
Several institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its stake in Tarsus Pharmaceuticals by 2,088.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock worth $14,477,000 after purchasing an additional 420,057 shares during the period. Vestal Point Capital LP bought a new position in shares of Tarsus Pharmaceuticals during the third quarter worth $7,565,000. Jennison Associates LLC grew its stake in Tarsus Pharmaceuticals by 14.8% during the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock valued at $138,432,000 after acquiring an additional 321,552 shares in the last quarter. Verition Fund Management LLC bought a new stake in Tarsus Pharmaceuticals in the 3rd quarter valued at $763,000. Finally, Mutual of America Capital Management LLC purchased a new stake in Tarsus Pharmaceuticals in the 3rd quarter worth $4,291,000. Hedge funds and other institutional investors own 90.01% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on TARS shares. Jefferies Financial Group boosted their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. HC Wainwright reaffirmed a "buy" rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Guggenheim reiterated a "buy" rating and issued a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Barclays reduced their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Finally, Oppenheimer raised their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Tarsus Pharmaceuticals has an average rating of "Buy" and an average target price of $63.67.
Check Out Our Latest Stock Report on Tarsus Pharmaceuticals
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
